Wind farms are ruining the electricity market

Wind farms are ruining the electricity market

While Australia’s energy market operator continues its investigation into South Australia’s recent state-wide blackout, there are important questions being asked.

For instance, was extreme weather the only cause? Has South Australia replaced fossil fuels with renewables too quickly?

Biofuels are a climate mistake

Biofuels are a climate mistake

Ever since the 1973 oil embargo, U.S. energy policy has sought to replace petroleum-based transportation fuels with alternatives. One prominent option is using biofuels, such as ethanol in place of gasoline and biodiesel instead of ordinary diesel.

Transportation generates one-fourth of U.S. greenhouse gas emissions, so addressing this sector’s impact is crucial for climate protection.

Computers should be able to hold patents

The rapid increase in creative computing is posing new challenges when it comes to patenting an invention. Artificial intelligence is playing an ever larger role in innovation -- with major players such as IBM, Pfizer and Google investing heavily in the field.

CRISPR-Cas9 gene editing paves way for sickle cell cure

A team of physicians and laboratory scientists has taken a key step toward a cure for sickle cell disease, using CRISPR-Cas9 gene editing to fix the mutated gene responsible for the disease in stem cells from the blood of affected patients. For the first time, they have corrected the mutation in a proportion of stem cells that is high enough to produce a substantial benefit in sickle cell patients.

Antipsychotic medications linked to increased risk of pneumonia in persons with Alzheimer's disease

Antipsychotic medications are associated with an increased risk of pneumonia in persons with Alzheimer's disease (AD), according to new research from the University of Eastern Finland. The risk of pneumonia was the highest at the beginning of antipsychotic treatment, remaining elevated also in long-term use. No major differences were observed between the most commonly used antipsychotics.

Therapeutic Gene Delivery for Inherited Retinal Degeneration in Children

Researchers have demonstrated the ability to deliver a fully functional copy of the CLN3 gene to stem cells of patients with juvenile NCL, an inherited neurodegenerative disease in which a mutation in the CLN3 gene causes early-onset severe central vision loss. The gene therapy restored production of CLN3 protein in the stem cell-derived retinal neurons, as described in an article in Human Gene Therapy.

Molecular atlas of the pancreas

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between people with type 2 diabetes and healthy controls. The study, which is published in Cell Metabolism, was conducted in the AstraZeneca and Karolinska Institutet co-run Integrated Cardio Metabolic Centre, and in association with researchers from AstraZeneca.

Modeling radiation damage

In nuclear reactors, energetic neutrons slam into metal atoms that are ordered in a lattice, displacing them with enough force to trigger a cascade of collisions. Laurent Béland,Yuri Osetsky and Roger Stoller, of the Energy Dissipation to Defect Evolution Energy Frontier Research Center at the Department of Energy's Oak Ridge National Laboratory, modeled radiation damage and discovered that the number of defects ultimately created in a material correlates with atomic displacements that high-pressure shock waves generate early in the collision cascade.

Cleaner coatings for solar

Keeping energy-concentrating mirrors at solar thermal power plants free from dirt is both labor and time intensive. Researchers at Oak Ridge National Laboratory are working to address the challenge with lab-developed superhydrophobic coating technology.

A rapid and effective antidote for anticoagulant bleeds

A specially designed antidote to reverse acute, potentially life-threatening anticoagulant-related bleeding worked quickly, and was well-tolerated according to interim results of the ongoing ANNEXA-4 study.

Andexanet alfa reduced anticoagulant activity by roughly 90% within half an hour among patients with acute major bleeding while receiving a factor Xa (fXa) inhibitor, resulting in "excellent or good" homeostatis at 12 hours in most subjects, reported lead investigator Stuart J. Connolly, MD, from McMaster University, in Hamilton Ontario, Canada.